PEPTONIC Medical AB: Peptonic Medical's request for extension of company reconstruction approved by Uppsala District Court
Peptonic Medical AB (publ) ("Peptonic" or the "Company") announces that the Uppsala District Court has today, June 17 2025, approved the Company's request to extend the ongoing company reconstruction by three months, until 15 September 2025. The extension is in line with the previously communicated timeline and aims to allow finalization of a reconstruction plan and the initiation of plan proceedings in accordance with the Swedish Company Reconstruction Act.
Uppsala District Court has today approved the Company's request to extend the ongoing company reconstruction by three months, until 15 September 2025. The request, submitted on 8 June 2025, aligns with the earlier communicated plan, under which the reconstruction is expected to be completed within three to six months from the application date. During the extension period, the Company intends to finalize the reconstruction plan, negotiate with relevant stakeholders, and initiate formal plan proceedings under the Company Reconstruction Act. In parallel, the Company continues to pursue its key commercial initiatives in the Nordic and U.S. markets.
The Board of Directors believes that the planned reconstruction measures, including a direct share issue and set-off issues, are necessary and sufficient to restore the Company's financial stability and ensure continued operations.
For further information, please contact:
Anna Linton, CEO, Peptonic Medical AB
Email: anna.linton@peptonicmedical.se
Phone: +46 70-244 92 07
About Peptonic Medical AB
PEPTONIC medical AB (publ) is a pioneering Swedish medtech company specializing in the development and sale of clinically proven self-care products for women's intimate health. Through its brands VagiVital and Vernivia, the Company offers a broad over-the-counter portfolio of effective and gentle products designed to help women understand, treat, and prevent common medical conditions in the intimate area. Peptonic's growth strategy centers on geographic expansion, particularly in the U.S. and Europe, while continually enhancing its product portfolio through in-house development and strategic acquisitions.
The Company is headquartered in Stockholm, Sweden, and operates the subsidiaries, Peptonic Medical Inc. and Common Sense Marketing Inc., in the U.S. Peptonic Medical was founded in 2009 and has been listed on the Spotlight Stock Market since 2014.